Ehlers-Danlos Syndrome Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 9 studies associated with Ehlers-Danlos Syndrome.
Here is a small sampling of Ehlers-Danlos Syndrome studies by title:
- Use of complementary and alternative medicine by patients with hypermobile Ehlers-Danlos Syndrome: A qualitative study
- The Internet Knows More Than My Physician: Qualitative Interview Study of People With Rare Diseases and How They Use Online Support Groups
- Treating pain related to Ehlers-Danlos syndrome with medical cannabis
- Use of complementary therapies for chronic pain management in patients with reported Ehlers-Danlos syndrome or hypermobility spectrum disorders
Components of the Ehlers-Danlos Syndrome Research Dashboard
- Dosing information available for Ehlers-Danlos Syndrome
- Chemotype guidance for treating Ehlers-Danlos Syndrome with cannabis
- Synopsis of cannabis research for Ehlers-Danlos Syndrome
- Individual study details for Ehlers-Danlos Syndrome
Ready to become a subscriber? Go to our PRICING page.
Ehlers-Danlos Syndrome Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 9 studies associated with Ehlers-Danlos Syndrome.
Here is a small sampling of Ehlers-Danlos Syndrome studies by title:
- Use of complementary and alternative medicine by patients with hypermobile Ehlers-Danlos Syndrome: A qualitative study
- The Internet Knows More Than My Physician: Qualitative Interview Study of People With Rare Diseases and How They Use Online Support Groups
- Treating pain related to Ehlers-Danlos syndrome with medical cannabis
- Use of complementary therapies for chronic pain management in patients with reported Ehlers-Danlos syndrome or hypermobility spectrum disorders
Components of the Ehlers-Danlos Syndrome Research Dashboard
- Dosing information available for Ehlers-Danlos Syndrome
- Chemotype guidance for treating Ehlers-Danlos Syndrome with cannabis
- Synopsis of cannabis research for Ehlers-Danlos Syndrome
- Individual study details for Ehlers-Danlos Syndrome
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Ehlers-Danlos Syndrome
Description of Ehlers-Danlos Syndrome
Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders characterized by specific collagen production or processing defects affecting the skin, joints, and blood vessels. Symptoms vary widely depending on the type of EDS, but often include hypermobile joints, stretchy and fragile skin, easy bruising, and chronic pain. In more severe cases, complications such as frequent joint subluxation or dislocations, organ or blood vessel rupture, and poor wound healing and scarring can occur, significantly impacting quality of life.
EDS is caused by genetic mutations that impair the structure or processing of collagen, a key protein for tissue strength and elasticity. Diagnosis typically involves clinical evaluation, family history, and, in some cases, genetic testing. Specialists are frequently involved to manage and monitor the respective affected areas, especially the heart, and pregnancy may be quickly complicated.
While there is no cure, treatment focuses on symptom management, such as physical therapy to strengthen muscles, pain relief, and preventive measures to avoid injury. Early diagnosis and tailored care are crucial for improving patient outcomes.
Disease Classification
Condition: Ehlers-Danlos SyndromeDisease Family: Genetic Connective Tissue Disorder
Organ System: Muscular System
ICD-10 Chapter: Congenital Malformations, Deformations and Chromosomal Abnormalities
ICD-10 Code: Q79.6
Ehlers-Danlos Syndrome Symptoms:
Muscular-skeletal hyperflexibility (e.g. spontaneous joint dislocation, subluxation, chronic joint disorders, chronic sprains/strains), severe pain, cardiac abnormalities, fragile, doughy, and hyperextensible skin, with thin, atrophic scarringAlso known as:
EDS, Ehlers-Danlos Syn.Drug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
